Soleno Therapeutics, Inc. Common Stock
SLNO
$53.01
+0.04%
Soleno Therapeutics is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, with its lead product candidate being DCCR (Diazoxide Choline) Extended-Release tablets, a proprietary formulation targeting the KATP channel. The company operates as a niche player in the biotechnology sector, specifically targeting rare disease markets with its sole therapeutic product, VYKAT XR. The current investor narrative is dominated by a significant corporate event, as recent news headlines indicate Neurocrine Biosciences is acquiring Soleno to access its high-growth rare disease drug, a strategic move that has fundamentally reshaped the stock's outlook. Concurrently, the company is facing a securities fraud lawsuit alleging it misled investors about the safety and commercial prospects of DCCR, adding a layer of legal overhang to the acquisition-driven price action.…
SLNO
Soleno Therapeutics, Inc. Common Stock
$53.01
Related headlines
Investment Opinion: Should I buy SLNO Today?
Rating: Hold. The core thesis is that the stock is fairly valued for the pending acquisition, with limited near-term upside but significant downside if the deal breaks.
Supporting evidence includes the stock's consolidation just above $52 for over a month, suggesting the market has efficiently priced in the acquisition news. The explosive 3-month return of 42.35% has likely captured the majority of the immediate deal premium. While profitability metrics are strong (44.08% operating margin), the valuation is stretched at a 117.86x trailing P/E and a 12.93x PS ratio. The lack of a consensus analyst price target further complicates assessing fair value, leaving the acquisition price as the primary benchmark.
The thesis would upgrade to Buy if the acquisition receives definitive regulatory approval, eliminating closure risk and potentially triggering a final move toward the deal price. It would downgrade to Sell if the deal is terminated or the lawsuit escalates materially, likely causing a crash toward the $30 support level. Relative to its own history and the binary nature of the event, the stock is fairly valued at current levels, balancing the high probability of deal completion against the catastrophic risk of its failure.
Sign up to view all
SLNO 12-Month Price Forecast
The investment narrative for SLNO has been entirely subsumed by the pending acquisition. The current price action reflects a market efficiently pricing in a high probability of deal completion. The neutral stance is based on the asymmetric risk/reward: limited upside to a slightly higher takeout price versus significant downside if the deal fails. Confidence is medium due to the remaining legal overhang and the extreme valuation multiple. The stance would upgrade to bullish only upon definitive deal closure, and would immediately turn bearish upon any official announcement of deal termination or material renegotiation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Soleno Therapeutics, Inc. Common Stock's 12-month outlook, with a consensus price target around $68.91 and implied upside of +30.0% versus the current price.
Average Target
$68.91
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$42 - $69
Analyst target range
Insufficient analyst coverage data is available to determine a consensus price target, Buy/Hold/Sell distribution, or implied upside/downside. The provided data includes estimated EPS and revenue averages but lacks explicit target prices or recommendation counts. This limited coverage is typical for small to mid-cap biotechnology companies, especially those with a recent transformative event like an acquisition, which can lead to higher volatility and less efficient price discovery as the investment story is reassessed. The institutional ratings data shows a pattern of consistent 'Buy' or 'Overweight' ratings from firms like Oppenheimer, HC Wainwright, Wells Fargo, and TD Cowen throughout 2025 and early 2026, with no downgrades visible in the recent period. This sustained bullish sentiment from covering analysts, despite the securities lawsuit news, suggests fundamental conviction in the product's potential. The lack of a defined target price range, however, means the signal strength from analyst sentiment is qualitative rather than quantitative, with the acquisition itself serving as the definitive valuation catalyst superseding traditional analyst targets.
Drowning in data?
Find the real signal!
Bulls vs Bears: SLNO Investment Factors
The evidence is strongly bifurcated, with bullish factors driven by a transformative corporate event and bearish factors rooted in valuation and legal risks. The bull side currently holds stronger evidence, as the acquisition provides a concrete, near-term catalyst that has already re-rated the stock by over 40%. However, the single most important tension is the execution risk of the acquisition against the backdrop of an extreme valuation multiple. If the deal closes smoothly at or near the current implied valuation, bulls win. If the deal is delayed, renegotiated, or jeopardized by the lawsuit, the stock could rapidly retrace towards its pre-announcement levels, delivering significant losses to current holders.
Bullish
- Acquisition by Neurocrine Biosciences: The definitive acquisition by Neurocriere provides a strategic exit and validates the commercial potential of VYKAT XR. The stock's 42.35% surge over 3 months is directly attributable to this news, with the price consolidating tightly around the $52-$53 level, indicating the market has priced in the deal's completion.
- Quarterly revenue grew from $0 to $91.73 million within a year, with Q4 2025 net income of $43.36 million. The company achieved a 99.06% gross margin and a 44.08% operating margin, demonstrating a successful transition to a profitable commercial-stage biotech.
- Strong, Debt-Free Balance Sheet: The company has minimal financial risk with a debt-to-equity ratio of 0.006 and a robust current ratio of 5.80. Positive free cash flow of $46.90 million TTM provides ample liquidity and strengthens its position heading into the acquisition.
- Sustained Analyst Conviction: Despite the securities lawsuit, institutional analysts from Oppenheimer, HC Wainwright, Wells Fargo, and TD Cowen have maintained consistent 'Buy' or 'Overweight' ratings throughout 2025 and early 2026. This sustained bullish sentiment underscores fundamental belief in the product's value.
Bearish
- Extreme Valuation on Trailing Earnings: The stock trades at an extremely high trailing P/E of 117.86x, which is 8.3x higher than its own historical P/E of 14.20x. This indicates the price is disconnected from current earnings power and is instead pricing in the acquisition premium and future growth, creating vulnerability if the deal faces hurdles.
- Pending Securities Fraud Lawsuit: An active lawsuit alleges the company misled investors about DCCR's safety and commercial prospects, which contributed to the stock's 52-week low of $29.43. This legal overhang could complicate the acquisition process or lead to settlements that diminish shareholder value.
- Single-Product, Event-Driven Dependency: The entire investment thesis is now binary and dependent on the successful completion of the Neurocrine acquisition. The company's revenue is 100% concentrated in VYKAT XR, and its stock exhibits extreme, non-systemic volatility with a beta of -2.217, making it highly speculative.
- Forward Earnings Uncertainty: Analyst estimates project a return to losses, with a negative forward P/E of -23.35x, contrasting sharply with recent quarterly profits. This gap signals high uncertainty around the company's standalone financial trajectory post-acquisition announcement and potential one-time charges.
SLNO Technical Analysis
The stock is in a pronounced downtrend over the past year, with a 1-year price change of -29.39%, but has recently experienced a dramatic reversal. The current price of $53.01 sits at approximately 25% of its 52-week range ($29.43 to $90.32), indicating it is trading much closer to its annual low than its high, which historically suggested a deep value or distress situation prior to the recent catalyst. However, this positioning has been radically altered by a massive short-term surge, with the stock up 42.35% over the past 3 months, decisively breaking the longer-term downtrend. The 1-month price change of 0.84% is positive but modest compared to the explosive 3-month move, suggesting the initial surge from the acquisition news in early April has consolidated into a tight, elevated trading range, as evidenced by the price clustering tightly around $52-$53 for over a month. Recent momentum shows a stark divergence from the longer-term trend, with the 3-month surge of 42.35% completely reversing the negative 1-year performance. The 1-month gain of 0.84% indicates momentum has decelerated sharply following the initial spike, entering a consolidation phase. This divergence signals a fundamental catalyst-driven trend reversal rather than a simple mean reversion, with the stock's relative strength versus the SPY being highly positive over 3 months at +33.93% but deeply negative over 1 year at -54.58%, highlighting the abrupt shift in market perception. The beta of -2.217 is an extreme outlier, indicating the stock's price movements have been inversely correlated with the broader market, which is atypical and likely reflects its binary, event-driven nature. Key technical levels are the 52-week low of $29.43, which served as a base before the April surge, and the 52-week high of $90.32, representing substantial overhead resistance. The explosive move from around $30 to above $52 constituted a massive breakout, but the stock now faces resistance near its recent consolidation highs. A sustained breakdown below the new support zone around $50 would signal the acquisition premium is eroding, while a breakout above $55 could indicate further positive developments. The stock's extreme negative beta of -2.217 underscores its idiosyncratic, non-systemic risk profile, making it highly volatile and uncorrelated, which drastically alters standard risk management considerations for this name.
Beta
-2.22
-2.22x market volatility
Max Drawdown
-66.0%
Largest decline past year
52-Week Range
$29-$90
Price range past year
Annual Return
-29.4%
Cumulative gain past year
| Period | SLNO Return | S&P 500 |
|---|---|---|
| 1m | +0.8% | +3.3% |
| 3m | +42.3% | +6.9% |
| 6m | +7.3% | +12.4% |
| 1y | -29.4% | +23.4% |
| ytd | +12.4% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SLNO Fundamental Analysis
Revenue trajectory has transformed from non-existent to significant, with the most recent quarterly revenue for Q4 2025 at $91.73 million, representing a massive sequential increase from $66.02 million in Q3 2025 and $32.66 million in Q2 2025. Prior to Q2 2025, the company reported zero revenue for multiple quarters, indicating the commercial launch or significant licensing of its product has recently commenced. This explosive growth from $0 to $91.73 million in quarterly sales within a year is the core driver of the fundamental re-rating, with the 'Product' segment being the sole revenue source at $32.66 million as of the last segment disclosure. Profitability has swung dramatically from deep losses to substantial profits, with net income for Q4 2025 at $43.36 million, compared to a net loss of -$47.08 million in Q2 2025 and -$43.77 million in Q1 2025. Gross margin is exceptionally high at 99.06% for Q4 2025, which is typical for a commercial-stage biotech with proprietary therapeutics. The operating margin for the same quarter was 44.08%, indicating the company has achieved operational profitability on its core business, a critical inflection point that validates its commercial model and likely underpins the acquisition interest. The balance sheet is strong, with a very low debt-to-equity ratio of 0.006 and a robust current ratio of 5.80, indicating ample liquidity and minimal financial leverage risk. The company generated positive free cash flow of $46.90 million on a TTM basis and $48.65 million in the latest quarter, demonstrating an ability to fund operations internally. Return on equity (ROE) was 4.64% and return on assets (ROA) was 12.07%, metrics that have turned positive from deeply negative levels, reflecting the successful monetization of its drug pipeline and improved capital efficiency post-revenue generation.
Quarterly Revenue
$91730000.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
99.1%
Latest Quarter
Free Cash Flow
$46903000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SLNO Overvalued?
Given the company's positive net income of $43.36 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 117.86x, which is extremely high, while the forward PE is negative at -23.35x, indicating analyst estimates project a return to losses, likely due to anticipated acquisition-related costs or one-time charges; this wide gap signals high uncertainty and a transition period in the company's financial profile. Peer comparison is challenging due to the company's unique rare disease focus and acquisition context, but available valuation multiples show a PS ratio of 12.93x and an EV/Sales of 8.98x. Without explicit industry average data provided, the high gross margin of 99.06% and recent profitability could justify a premium to unprofitable biotech peers, but the elevated trailing PE suggests the market is pricing in significant future growth or the acquisition takeout premium, rather than current earnings power. Historical context shows the current trailing PE of 117.86x is vastly higher than its own historical PE of 14.20x as of Q4 2025, indicating the stock has re-rated massively to the upside. The current PS ratio of 12.93x is below its historical PS of 26.84x from Q4 2025, suggesting the sales multiple has compressed even as the price surged, due to the explosive growth in the revenue base. Trading near its own historical valuation highs on a PE basis reflects the market's incorporation of the acquisition premium and optimistic expectations for the commercial rollout of its rare disease drug.
PE
117.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -225x~35x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
84.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are currently muted due to the acquisition context but were previously severe. The company's historical dependency on a single product (VYKAT XR) and its journey from deep losses (net loss of -$47.08M in Q2 2025) to profitability in one quarter illustrates extreme earnings volatility. While the balance sheet is now strong, the forward P/E of -23.35x indicates analysts expect a return to losses, highlighting uncertainty around the sustainability of its newfound profitability outside of the acquisition framework.
Market & Competitive Risks are dominated by event-specific and legal factors. The stock's extreme negative beta of -2.217 confirms it trades on idiosyncratic news, not market fundamentals, making it highly volatile and unpredictable. The primary risk is valuation compression if the acquisition premium erodes; the trailing P/E of 117.86x represents a massive premium that could deflate if deal sentiment sours. Furthermore, the securities fraud lawsuit presents a tangible regulatory and reputational headwind that could delay or alter the acquisition terms, as highlighted by recent news of the legal deadline alert.
Worst-Case Scenario involves the Neurocrine acquisition falling through due to regulatory issues, litigation findings, or a material adverse change. In this scenario, the stock would likely collapse back to its pre-announcement trading range, anchored by the 52-week low of $29.43. Given the stock's historical max drawdown of -66.04%, a realistic downside from the current price of $53.01 could be approximately -45%, bringing the share price to the low-$30s. This would represent a total loss of the recent 42% surge and a return to pricing based on standalone fundamentals, which include the lawsuit overhang and uncertain forward earnings.
FAQ
The key risks are, in order of severity: 1) Deal Failure Risk: The acquisition by Neurocrine could collapse due to regulatory, legal, or business reasons, potentially crashing the stock to its 52-week low of $29.43. 2) Legal Risk: The active securities fraud lawsuit alleging misleading statements about DCCR could result in costly settlements or damage the company's reputation, complicating the acquisition. 3) Concentration Risk: The company's entire value is tied to one product (VYKAT XR), creating binary commercial dependency. 4) Volatility Risk: The stock's extreme negative beta of -2.217 means its price movements are uncorrelated and unpredictable, driven solely by company-specific news.
The 12-month forecast is entirely contingent on the acquisition outcome. Our base case (65% probability) sees the stock trading in a tight range of $52-$55 upon successful deal closure. The bear case (10% probability) forecasts a collapse to $29-$40 if the deal fails, forcing a revaluation based on standalone fundamentals which include a negative forward P/E. The bull case (25% probability) anticipates minor delays but eventual completion, with the stock oscillating between $45-$52. The most likely scenario is the base case, predicated on the assumption that the acquisition, announced in April 2026, will close without major incident.
SLNO is fairly valued relative to the pending acquisition but extremely overvalued on a standalone fundamental basis. The trailing P/E of 117.86x is stratospheric and 8.3x higher than its own historical P/E, indicating the price reflects the acquisition premium, not earnings power. The PS ratio of 12.93x is more reasonable for a commercial-stage biotech with 99% gross margins but still reflects high expectations. The valuation implies the market assigns a very high probability to deal completion; any erosion in that confidence would cause a severe de-rating.
SLNO is a high-risk, event-driven speculation rather than a traditional 'good buy.' For investors who believe the Neurocrine acquisition will close smoothly at current terms, buying near $53 offers a small, final arb premium. However, the risk/reward is asymmetric, with limited upside (perhaps 0-4% to a final deal price) and significant downside (potentially -45% to pre-deal levels) if the transaction fails. It is only suitable for investors who can closely monitor deal-specific catalysts and tolerate the legal overhang from the pending securities fraud lawsuit.
SLNO is strictly a short-term, event-driven trade with a defined horizon tied to the acquisition's expected closing. It is unsuitable for long-term investment because post-acquisition, the stock will cease to exist as an independent entity. The ideal holding period is from now until the deal closes, which could be a matter of months. Given the stock's high volatility (beta of -2.217) and binary outcome, it should not be held passively. Investors should have a clear exit strategy upon deal completion or upon any news that jeopardizes the transaction.
